Details

Autor(en) / Beteiligte

• Fudala, Paul J
• Bridge, T. Peter
• Herbert, Susan
• Williford, William O
• Chiang, C. Nora
• Jones, Karen
• Collins, Joseph
• Raisch, Dennis
• Casadonte, Paul
• Goldsmith, R. Jeffrey
• Ling, Walter
• Malkerneker, Usha
• McNicholas, Laura
• Renner, John
• Stine, Susan
• Tusel, Donald

Titel

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Ist Teil von

• The New England journal of medicine, 2003-09, Vol.349 (10), p.949-958

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized, multicenter trial, office-based treatment of opiate-addicted persons for one month with buprenorphine or a combination of buprenorphine and naloxone (to discourage parenteral abuse of buprenorphine) was superior to placebo in reducing the frequency of opiate-positive urine tests and opiate cravings. Open-label follow-up for up to 52 weeks confirmed that the combination of buprenorphine and naloxone was safe and well tolerated. Buprenorphine and naloxone are useful and safe. Addiction to opiates, usually to heroin, remains a continuing problem in the United States and is increasing in Europe. 1 – 5 Opiate-substitution pharmacotherapy reduces the use of illicit opiates and the high-risk and criminal behaviors associated with it. 6 – 8 However, two currently available opiate-substitution therapies, methadone and levomethadyl acetate, are provided only in a strictly regulated environment in which medication is taken under clinical observation, with limited provision for take-at-home dosing. 9 Such monitoring is necessary because of concern about the diversion of these drugs to illicit use but is also known to dissuade many addicted persons from seeking help. 10 Furthermore, under . . .